MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: An Australian case-control-family study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Cust, Anne E ^a   Goumas, Chris ^a   Vuong, Kylie ^a   Davies, John R ^b   Barrett, Jennifer H ^b   Holland, Elizabeth A ^c   Schmid, Helen ^c   Agha Hamilton, Chantelle ^c   Armstrong, Bruce K ^a   Kefford, Richard F ^c   Aitken, Joanne F ^d   Giles, Graham G ^e,f   Bishop, D Timothy ^b   Newton Bishop, Julia A ^b   Hopper, John L ^e   Mann, Graham J ^c   Jenkins, Mark A ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

Accuracy; Early onset; MC1R; Melanoma; Nevi; Pigmentation; Risk prediction; Sun exposure

Indexed keywords

MELANOCORTIN 1 RECEPTOR;

ADULT; ARTICLE; AUSTRALIA; CANCER RISK; CONTROLLED STUDY; FAMILY STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCORTIN 1 RECEPTOR GENE; MELANOMA; NEVUS; NON MELANOMA SKIN CANCER; ONSET AGE; PIGMENTATION; POPULATION BASED CASE CONTROL STUDY; PREDICTION; SELF REPORT; SUN EXPOSURE; ADOLESCENT; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FAMILY; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; PHENOTYPE; PHYSICIAN; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SKIN NEOPLASMS; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AUSTRALIA; CASE-CONTROL STUDIES; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MELANOMA; MODELS, STATISTICAL; NEOPLASM STAGING; PHENOTYPE; PHYSICIANS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; ROC CURVE; SELF REPORT; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84883293845     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-406     Document Type: Article

References (52)

1. Australian Institute of Health and Welfare (AIHW) Cancer in Australia: an overview, 2008. Cancer Series no 46, AIHW cat no CAN 42 2008, Canberra: AIHW, Australian Institute of Health and Welfare (AIHW).
2. CancerStats - cancer statistics for the UK http://info.cancerresearchuk.org/cancerstats.
3. Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010, 126(2):450-458. 10.1002/ijc.24747, 19609948.
4. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, Katalinic A. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012, 66(2):201-211. 10.1016/j.jaad.2010.11.016, 22074699.
5. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41(1):28-44. 10.1016/j.ejca.2004.10.015, 15617989.
6. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41(1):45-60. 10.1016/j.ejca.2004.10.016, 15617990.
7. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41(14):2040-2059. 10.1016/j.ejca.2005.03.034, 16125929.
8. Newton-Bishop J, Gruis N. Melanoma susceptibility genes. Melanoma Res 2010, 20(3):161-162. 10.1097/CMR.0b013e328336b000, 20442621.
9. Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol 2012, 132(7):1763-1774. 10.1038/jid.2012.75, 22475760.
10. Savage SA, Gerstenblith MR, Goldstein AM, Mirabello L, Fargnoli MC, Peris K, Landi MT. Nucleotide diversity and population differentiation of the melanocortin 1 receptor gene, MC1R. BMC Genet 2008, 9:31. 2324112, 18402696.
11. Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007, 28(5):495-505. 10.1002/humu.20476, 17279550.
12. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008, 122(12):2753-2760. 10.1002/ijc.23396, 18366057.
13. Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, Rebbeck TR. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?. Cancer 2010, 116(10):2416-2428. 2864335, 20301115.
14. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin-1-receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011, 129(7):1730-1740. 10.1002/ijc.25804, 21128237.
15. Cust AE, Goumas C, Holland EA, Agha-Hamilton C, Aitken JF, Armstrong BK, Giles GG, Kefford RF, Schmid H, Hopper JL, et al. MC1R Genotypes and risk of melanoma before age 40 years: a population-based case-control-family study. Int J Cancer 2012, 131:E269-E281. 10.1002/ijc.27357, 22095472.
16. Whiteman DC, Green AC. A risk prediction tool for melanoma?. Cancer Epidemiol Biomarkers Prev 2005, 14(4):761-763. 10.1158/1055-9965.EPI-14-4-ED, 15824139.
17. Smith LA, Qian M, Ng E, Shao Y, Berwick M, Lazovich D, Polsky D. Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure. J Clin Oncol 2012, 30(suppl; abstr 8574).
18. Stefanaki I, Panagiotou OA, Kodela E, Gogas H, Kypreou KP, Chatzinasiou F, Nikolaou V, Plaka M, Kalfa I, Antoniou C, et al. Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. PLoS One 2013, 8(2):e55712. 10.1371/journal.pone.0055712, 3564929, 23393597.
19. Cust AE, Schmid H, Maskiell JA, Jetann J, Ferguson M, Holland EA, Agha-Hamilton C, Jenkins MA, Kelly J, Kefford RF, et al. Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: australian melanoma family study. Am J Epidemiol 2009, 170(12):1541-1554. 10.1093/aje/kwp307, 2800270, 19887461.
20. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009, 41(8):920-925. 10.1038/ng.411, 2741419, 19578364.
21. Cust AE, Jenkins MA, Goumas C, Armstrong BK, Schmid H, Aitken JF, Giles GG, Kefford RF, Hopper JL, Mann GJ. Early-life sun exposure and risk of melanoma before age 40 years. Cancer Causes Control 2011, 22(6):885-897. 10.1007/s10552-011-9762-3, 21472378.
22. English DR, MacLennan R, Rivers J, Kelly J, Armstrong BK. Epidemiological studies of melanocytic naevi: protocol for identifying and recording naevi 1990, Lyon (France): International Agency for Research on Cancer (IARC) internal report No. 90/002.
23. Dwyer T, Blizzard L, Ashbolt R. Sunburn associated with increased number of nevi in darker as well as lighter skinned adolescents of northern European descent. Cancer Epidemiol Biomarkers Prev 1995, 4(8):825-830.
24. Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. J Invest Dermatol 1992, 99(4):468-473. 10.1111/1523-1747.ep12616156, 1402005.
25. Creech LL, Mayer JA. Ultraviolet radiation exposure in children: a review of measurement strategies. Ann Behav Med 1997, 19(4):399-407. 10.1007/BF02895159, 9706367.
26. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010, 21(1):128-138. 10.1097/EDE.0b013e3181c30fb2, 3575184, 20010215.
27. Spitz MR, Amos CI, D'Amelio A, Dong Q, Etzel C. Re: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2009, 101(24):1731-1732. author reply 1732, 10.1093/jnci/djp394, 2794300, 19903803.
28. Pepe MS, Gu JW, Morris DE. The potential of genes and other markers to inform about risk. Cancer Epidemiol Biomarkers Prev 2010, 19(3):655-665. 10.1158/1055-9965.EPI-09-0510, 2836397, 20160267.
29. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27(2):157-172. discussion 207-112, 10.1002/sim.2929, 17569110.
30. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating 2009, New York, USA: Springer.
31. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest 2012, 42(2):216-228. 10.1111/j.1365-2362.2011.02562.x, 3587963, 21726217.
32. Newton-Bishop JA, Chang YM, Iles MM, Taylor JC, Bakker B, Chan M, Leake S, Karpavicius B, Haynes S, Fitzgibbon E, et al. Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev 2010, 19(8):2043-2054. 10.1158/1055-9965.EPI-10-0233, 2923062,2923062, 20647408.
33. English DR, Armstrong BK. Identifying people at high risk of cutaneous malignant melanoma: results from a case-control study in Western Australia. Br Med J (Clin Res Ed) 1988, 296(6632):1285-1288.
34. Fears TR, Guerry D, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006, 24(22):3590-3596. 10.1200/JCO.2005.04.1277, 16728488.
35. Williams LH, Shors AR, Barlow WE, Solomon C, White E. Identifying persons at highest risk of melanoma using self-assessed risk factors. J Clin Exp Dermatol Res 2011, 2(6).
36. Guther S, Ramrath K, Dyall-Smith D, Landthaler M, Stolz W. Development of a targeted risk-group model for skin cancer screening based on more than 100,000 total skin examinations. J Eur Acad Dermatol Venereol 2012, 26(1):86-94. 10.1111/j.1468-3083.2011.04014.x, 21371132.
37. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005, 23(12):2669-2675.
38. Harbauer A, Binder M, Pehamberger H, Wolff K, Kittler H. Validity of an unsupervised self-administered questionnaire for self-assessment of melanoma risk. Melanoma Res 2003, 13(5):537-542. 10.1097/00008390-200310000-00013, 14512796.
39. Barbini P, Cevenini G, Rubegni P, Massai MR, Flori ML, Carli P, Andreassi L. Instrumental measurement of skin colour and skin type as risk factors for melanoma: a statistical classification procedure. Melanoma Res 1998, 8(5):439-447. 10.1097/00008390-199810000-00009, 9835458.
40. Fortes C, Mastroeni S, Bakos L, Antonelli G, Alessandroni L, Pilla MA, Alotto M, Zappala A, Manoorannparampill T, Bonamigo R, et al. Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 2010, 19(5):393-400. 10.1097/CEJ.0b013e32833b492f, 20520559.
41. Quereux G, Moyse D, Lequeux Y, Jumbou O, Brocard A, Antonioli D, Dreno B, Nguyen JM. Development of an individual score for melanoma risk. Eur J Cancer Prev 2011, 20(3):217-224. 10.1097/CEJ.0b013e32834474ae, 21399503.
42. Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003, 120(2):217-223. 10.1046/j.1523-1747.2003.12041.x, 12542525.
43. Cust AE, Armstrong BK, Goumas C, Jenkins MA, Schmid H, Hopper JL, Kefford RF, Giles GG, Aitken JF, Mann GJ. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer 2011, 128(10):2425-2435. 10.1002/ijc.25576, 2993823, 20669232.
44. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159(9):882-890. 10.1093/aje/kwh101, 15105181.
45. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355(25):2615-2617. 10.1056/NEJMp068249, 17182986.
46. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007, 17(9):643-653. 10.1016/j.annepidem.2007.03.013, 17553702.
47. Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenny M, McKinney P, Modan B, Sadetzki S, et al. The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 2007, 22(9):647-664. 10.1007/s10654-007-9152-z, 17636416.
48. Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 2006, 66(18):9330-9337. 10.1158/0008-5472.CAN-06-1634, 16982779.
49. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008, 299(11):1335-1344. 10.1001/jama.299.11.1335, 18349094.
50. Collins FS, Green ED, Guttmacher AE, Guyer MS, . Institute USNHGR A vision for the future of genomics research. Nature 2003, 422(6934):835-847. 10.1038/nature01626, 12695777, Institute USNHGR.
51. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009, 101(13):959-963. 10.1093/jnci/djp130, 2704229, 19535781.
52. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005, 97(10):715-723. 10.1093/jnci/dji128, 15900041.